- Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Expires: February 28, 2011 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

SENYEI ANDREW E

2. Date of Event Requiring Statement (MM/DD/YYYY) 11/10/2010

3. Issuer Name and Ticker or Trading Symbol

COMPLETE GENOMICS INC [GNOM]

(Last) (First) (Middle)

C/O ENTERPRISE PARTNERS, 2223 AVENIDA DE LA PLAYA, SUITE 300

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director ___ X ___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

LA JOLLA, CA 92037-3218

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.001	7856	I	See Footnote ⁽⁸⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Preferred Stock ⁽¹⁾	⁽²⁾	⁽³⁾	Common Stock	315746	$0.00	I	See Footnote ⁽⁴⁾
Series B Preferred Stock ⁽⁵⁾	⁽²⁾	⁽³⁾	Common Stock	257677	$0.00	I	See Footnote ⁽⁴⁾
Series C Preferred Stock ⁽⁶⁾	⁽²⁾	⁽³⁾	Common Stock	177084	$0.00	I	See Footnote ⁽⁴⁾
Series D Preferred Stock ⁽⁷⁾	⁽²⁾	⁽³⁾	Common Stock	488789	$0.00	I	See Footnote ⁽⁴⁾
Series D Preferred Stock ⁽⁷⁾	⁽²⁾	⁽³⁾	Common Stock	66138	$0.00	I	See Footnote ⁽⁸⁾
Series D Preferred Stock ⁽⁷⁾	⁽²⁾	⁽³⁾	Common Stock	176737	$0.00	I	See Footnote ⁽⁹⁾
Series E Preferred Stock ⁽⁷⁾	⁽²⁾	⁽³⁾	Common Stock	547094	$0.00	I	See Footnote ⁽⁴⁾
Series E Preferred Stock ⁽⁷⁾	⁽²⁾	⁽³⁾	Common Stock	27049	$0.00	I	See Footnote ⁽⁸⁾
Series E Preferred Stock ⁽⁷⁾	⁽²⁾	⁽³⁾	Common Stock	259458	$0.00	I	See Footnote ⁽⁹⁾
Warrant to Purchase Common Stock	⁽¹⁰⁾	8/12/2016	Common Stock	308930	$1.50	I	See Footnote ⁽⁴⁾
Warrant to Purchase Common Stock	⁽¹⁰⁾	8/12/2016	Common Stock	138794	$1.50	I	See Footnote ⁽⁹⁾
Warrant to Purchase Common Stock	⁽¹⁰⁾	4/12/2015	Common Stock	96667	$1.50	I	See Footnote ⁽⁴⁾
Warrant to Purchase Common Stock	⁽¹⁰⁾	4/12/2015	Common Stock	34800	$1.50	I	See Footnote ⁽⁹⁾
Warrant to Purchase Common Stock	⁽¹⁰⁾	6/22/2015	Common Stock	31513	$1.50	I	See Footnote ⁽⁴⁾
Warrant to Purchase Common Stock	⁽¹⁰⁾	6/22/2015	Common Stock	21008	$1.50	I	See Footnote ⁽⁹⁾
Warrant to Purchase Series B Preferred Stock ⁽⁵⁾	⁽¹⁰⁾	2/21/2012	Series B Preferred	924	$11.642 ⁽¹¹⁾	I	See Footnote ⁽⁴⁾
Warrant to Purchase Series B Preferred Stock ⁽⁵⁾	⁽¹⁰⁾	3/12/2012	Series B Preferred	242	$11.642 ⁽¹¹⁾	I	See Footnote ⁽⁴⁾
Warrant to Purchase Series D Preferred Stock ⁽⁷⁾	⁽¹⁰⁾	2/13/2014	Series D Preferred	32364	$7.56	I	See Footnote ⁽⁴⁾
Warrant to Purchase Series D Preferred Stock ⁽⁷⁾	⁽¹⁰⁾	4/6/2014	Series D Preferred	17261	$7.56	I	See Footnote ⁽⁴⁾
Warrant to Purchase Series D Preferred Stock ⁽⁷⁾	⁽¹⁰⁾	4/6/2014	Series D Preferred	17261	$7.56	I	See Footnote ⁽⁹⁾
Warrant to Purchase Series D Preferred Stock ⁽⁷⁾	⁽¹⁰⁾	6/12/2014	Series D Preferred	2958	$7.56	I	See Footnote ⁽⁴⁾
Warrant to Purchase Series D Preferred Stock ⁽⁷⁾	⁽¹⁰⁾	6/12/2014	Series D Preferred	8378	$7.56	I	See Footnote ⁽⁹⁾
Warrant to Purchase Series D Preferred Stock ⁽⁷⁾	⁽¹⁰⁾	8/5/2014	Series D Preferred	1096	$7.56	I	See Footnote ⁽⁴⁾

Explanation of Responses:
( 1)	Each share of Series A Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. Shares are reported on an "as converted" basis giving effect to the 4.615101 conversion ratio applicable to such shares.
( 2)	The securities are immediately convertible.
( 3)	The expiration date is not relevant to the conversion of these securities.
( 4)	The shares are owned by Enterprise Partners VI, LP ("Enterprise VI"). Enterprise Management Partners VI, LLC ("Enterprise VI LLC") serves as the general partner of Enterprise VI. Andrew E. Senyei, M.D. is a managing director of Enterprise VI LLC and shares voting and investment power over the shares held by Enterprise VI. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.
( 5)	Each share of Series B Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. Shares are reported on an "as converted" basis giving effect to the 5.926613 conversion ratio applicable to such shares.
( 6)	Each share of Series C Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. Shares are reported on an "as converted" basis giving effect to the 8.241076 conversion ratio applicable to such shares.
( 7)	Each share of Series D and Series E Preferred Stock will automatically convert on a 1 for 1 basis into common stock upon the closing of the Issuer's initial public offering.
( 8)	The shares are owned by Enterprise Partners Management, LLC ("Enterprise LLC"). Andrew E. Senyei, M.D. is a managing director of Enterprise LLC and shares voting and investment power over the shares held by Enterprise LLC. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.
( 9)	The shares are owned by Enterprise Partners V, LP ("Enterprise V"). Enterprise Management Partners V, LLC ("Enterprise V LLC") serves as the general partner of Enterprise V. Andrew E. Senyei, M.D. is a managing director of Enterprise V LLC and shares voting and investment power over the shares held by Enterprise V. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.
( 10)	The warrant is immediately exercisable.
( 11)	The Exercise Price of the Warrant to Purchase Series B Preferred Stock is $69.00 per share of Series B Preferred Stock. Such warrants will become exercisable for shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The exercise price is reported on an "as converted" basis after giving effect to the 5.926613 conversion ratio.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
SENYEI ANDREW E C/O ENTERPRISE PARTNERS 2223 AVENIDA DE LA PLAYA, SUITE 300 LA JOLLA, CA 92037-3218	X	X

Signatures
/s/ Andrew E. Senyei		11/10/2010
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.